Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
imapextide
- Development stage
- Discontinued
- Lead developer
- MBX Biosciences
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
Imapextide (MBX 1416) is a precision peptide therapy developed by MBX Biosciences for endocrine and metabolic disorders. It is currently being investigated for the treatment of obesity and postbariatric hypoglycemia. The intellectual property underpinning imapextide was exclusively licensed from Indiana University Research and Technology Corporation.
02
Targets
Beyond the preview
Go deeper on imapextide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on imapextide.